Papillary thyroid microcarcinoma optimal management versus overtreatmentWalgama, Evana; Sacks, Wendy L.b; Ho, Allen S.aCurrent Opinion in Oncology: January 2020 - Volume 32 - Issue 1 - p 1–6 doi: 10.1097/CCO.0000000000000595 ENDOCRINE TUMORS: Edited by Christiane Jungels Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review The treatment of small, low-risk papillary thyroid carcinoma has undergone a paradigm shift, with many tumors now initially treated with active surveillance rather than upfront surgery. Further studies on patients enrolled in active surveillance have refined our knowledge of the clinical behavior of papillary thyroid microcarcinomas. Recent findings This article summarizes the major conclusions of landmark trials that launched active surveillance as a viable treatment option for selected patients. We discuss patient factors such as age and tumor size, the assessment of candidates for active surveillance, barriers to acceptance of active surveillance, quality of life issues, and economic considerations. Summary Active Surveillance is a viable first-line treatment option for select papillary microcarcinomas. aDepartment of Surgery, Division of Otolaryngology – Head and Neck Surgery bDepartment of Medicine, Division of Endocrinology, Cedars-Sinai Medical Center, Los Angeles, California, USA Correspondence to Allen S. Ho, MD, Department of Surgery, Division of Otolaryngology – Head and Neck Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. E-mail: firstname.lastname@example.org Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.